Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RENE.LSE
- Price
- -
- Stock movement down
- -0.07 (-2.17%)
- Company name
- ReNeuron Group plc
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 192.87M
- Ent value
- 191.79M
- Price/Sales
- 516.38
- Price/Book
- 79.66
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 0.47
- PEG
- -
- EPS growth
- -
- 1 year return
- -69.66%
- 3 year return
- -68.31%
- 5 year return
- -43.48%
- 10 year return
- -37.40%
Last updated: 2024-12-17
DIVIDENDS
RENE.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 516.38 |
| Price to Book | 79.66 |
| EV to Sales | 513.51 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 57.15M |
| EPS (TTM) | -0.13 |
| FCF per share (TTM) | -0.14 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 373.50K |
| Gross profit (TTM) | -629.00K |
| Operating income (TTM) | -9.21M |
| Net income (TTM) | -7.61M |
| EPS (TTM) | -0.13 |
| EPS (1y forward) | 7.18 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -168.41% |
| Operating margin (TTM) | -2466.27% |
| Profit margin (TTM) | -2037.35% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.08M |
| Net receivables | 670.00K |
| Total current assets | 5.75M |
| Goodwill | 0.00 |
| Intangible assets | 186.00K |
| Property, plant and equipment | 492.00K |
| Total assets | 6.42M |
| Accounts payable | 3.66M |
| Short/Current long term debt | 345.00K |
| Total current liabilities | 3.81M |
| Total liabilities | 4.00M |
| Shareholder's equity | 2.42M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -7.68M |
| Capital expenditures (TTM) | 96.00K |
| Free cash flow (TTM) | -7.78M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -314.31% |
| Return on Assets | -118.47% |
| Return on Invested Capital | -295.29% |
| Cash Return on Invested Capital | -301.90% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| RENE.LSE | S&P500 | |
| Current price drop from All-time high | -99.93% | -0.36% |
| Highest price drop | -99.93% | -56.47% |
| Date of highest drop | 5 Feb 2024 | 9 Mar 2009 |
| Avg drop from high | -88.16% | -11.07% |
| Avg time to new high | 90 days | 12 days |
| Max time to new high | 4284 days | 1805 days |
COMPANY DETAILS
Marketcap
192.87M
Marketcap category
Small-cap
Description
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Employees
26
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found